Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Respiratory function in Parkinson's disease.

H Shill1, M Stacy

  • 1Barrow Neurological Institute, Phoenix, Arizona, USA.

Clinical Neuroscience (New York, N.Y.)
|April 29, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical features of patients with blepharospasm: a report of 240 patients.

European journal of neurology·2010
Same author

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.

Neurology·2008
Same author

Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease.

Dementia and geriatric cognitive disorders·2007
Same author

Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.

Neurology·2006
Same author

Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996)·2006
Same author

BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study.

Neurology·2005
Same journal

Cardiovascular autonomic dysfunction in parkinsonian patients.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Visuo-cognitive dysfunctions in Parkinson's disease.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Gastrointestinal dysfunction in Parkinson's disease.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Neurophysiology of sensorimotor integration in Parkinson's disease.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Imaging of nonmotor symptoms in Parkinson syndromes.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Sleep dysfunction in Parkinson's disease.

Clinical neuroscience (New York, N.Y.)·2000
See all related articles

Parkinson's disease (PD) causes respiratory problems like chest rigidity and airway issues, which can be improved with medication. However, some treatments may lead to lung damage and infections, increasing PD patient mortality.

Area of Science:

  • Neurology
  • Pulmonology
  • Pharmacology

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder affecting motor function.
  • Respiratory dysfunction is a common non-motor symptom in PD.
  • Pulmonary complications significantly impact PD patient morbidity and mortality.

Purpose of the Study:

  • To review the range of respiratory dysfunctions in Parkinson's disease (PD).
  • To examine the effects of PD on ventilation and medication response.
  • To outline pulmonary complications associated with antiparkinsonian therapies.

Main Methods:

  • Literature review of respiratory dysfunction in Parkinson's disease.
  • Analysis of primary pulmonary abnormalities in PD.
  • Evaluation of medication-induced pulmonary complications.

Related Experiment Videos

Main Results:

  • PD causes restrictive lung changes due to chest wall rigidity and upper airway obstruction, responsive to dopaminergic drugs.
  • Levodopa therapy can induce respiratory dyskinesia, affecting ventilation.
  • Ergot derivative treatments may lead to pleuropulmonary fibrosis.
  • Pulmonary infections are a significant cause of mortality in PD patients due to impaired respiratory mechanics.

Conclusions:

  • Respiratory dysfunction is multifaceted in PD, involving primary effects and treatment complications.
  • Dopaminergic therapy can improve some PD-related respiratory issues.
  • Antiparkinsonian drugs carry risks of pulmonary fibrosis and infection.
  • Addressing respiratory complications is crucial for improving outcomes in Parkinson's disease.